GlassScriptPhysician profile
Reginald P Segar
NPI 1720057417
$3,089.11
in general payments reported to CMS, 2019-2025
19 companies · $77.49 in 2025
The $77.49 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $668 · 2020: $537 · 2021: $755 · 2022: $650 · 2023: $250 · 2024: $152 · 2025: $77.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $479.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $651.99 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $626.29 | 2019-2023 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $496.73 | 2019-2025 | Trelegy Ellipta |
| Pfizer INC. | $320.87 | 2019-2021 | |
| Abbvie INC. | $200.11 | 2021-2025 | |
| Lilly USA, LLC | $157.50 | 2019-2023 | Mounjaro |
| Allergan, INC. | $131.63 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $125.46 | 2021-2023 | |
| Amarin Pharma, INC. | $63.60 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.57 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $49.53 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.69 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.64 | 2023-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $30.31 | 2019 | |
| Shire North American Group INC | $29.55 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $24.02 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $17.44 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.18 | 2020 | |
| Merck Sharp & Dohme LLC | $15.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reginald Segar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.